Abstract:Although platinum-based chemotherapy remains the “standard” in advanced non small-cell lung cancer, not all patients derive clinical benefit from such a treatment. Hence, the development of predictive biomarkers able to identify lung cancer patients who are most likely to benefit from cisplatin-based chemotherapy has become a scientific priority. Among the molecular pathways involved in DNA damage control after chemotherapy, the nucleotide excision repair (NER) is a critical process for the repair of DNA damage caused by cisplatin-induced DNA adducts. Many reports have explored the role of the excision repair cross-complementation group 1 enzyme (ERCC1) expression in the repair mechanism of cisplatin-induced DNA adducts in cancer cells.Using immunohistochemistry in resected tumors from patients included in the International Adjuvant Lung Cancer Trial, the study of important biomarkers showed that high ERCC1 protein expression was associated with improved survival in chemo-naïve patients. On the contrary, the benefit of adjuvant cisplatin-based chemotherapy was more profound in patients with low ERCC1 expression. In a prospective cohort studying mRNA expression in tumor biopsies from patients receiving customized therapy with cisplatin and gemcitabine depending on the molecular profile of the tumour, results showed that patients with low ERCC1 mRNA expression had a longer median survival compared to those with high expression. These data suggest the potent use of ERCC1 as a molecular predictor of clinical resistance to platinum-based chemotherapy in the adjuvant setting of NSCLC. Nevertheless, optimization of methodology, including standardization of technical procedures, as well as validation of ERCC1 protein expression in large prospective cohorts, seem necessary before any routine immunohistochemical validation of ERCC1 can be implemented in daily practice.

ERCC1 abundance is an indicator of DNA repair-apoptosis decision upon DNA damage

Meta-analysis of excision repair cross-complementation group 1 (ERCC1) association with response to platinum- based chemotherapy in ovarian cancer.

High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.

Protein Expression Levels Of Excision Repair Cross-Complementation Group 1 And Xeroderma Pigmentosum D Correlate With Response To Platinum-Based Chemotherapy In The Patients With Advanced Epithelial Ovarian Cancer

Increased ERCC1 Protein Expression is Associated with Suboptimal Debulking in Advanced Epithelial Ovarian Cancer.

Excision Repair Cross-Complementation Group 1 Enzyme As a Molecular Determinant of Responsiveness to Platinum-Based Chemotherapy for Non Small-Cell Lung Cancer

DNA repair protein levels vis-à-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program.

Nucleotide Excision Repair Protein Levels Vis-À-vis Anticancer Drug Resistance in 60 Human Tumor Cell Lines.

Relationship Between ERCC1 Expression and Efficacy of Neoadjuvant Chemotherapy in the Patients with Non-Small-cell Lung Cancer

ERCC1, RRM1 and BRCA1 Mrna Expression Levels and Clinical Outcome of Advanced Non-Small Cell Lung Cancer.

Akt-Mediated Phosphorylation of XLF Impairs Non-Homologous End-Joining DNA Repair

Heterogeneous Nuclear Ribonucleoprotein L Facilitates Recruitment of 53BP1 and BRCA1 at the DNA Break Sites Induced by Oxaliplatin in Colorectal Cancer

XPA tumor variants lead to defects in NER that sensitize cells to cisplatin

XPA tumor variant leads to defects in NER that sensitize cells to cisplatin

The synergy between alkylating agents and ERCC1–XPF inhibitors is p53 dependent

Role of the human ERCC-1 gene in gene-specific repair of cisplatin-induced DNA damage

[ERCC1 Expression As a Predictor of Survival after Operation in Stage I Non-Small Cell Lung Cancer Patients].

ER-associated degradation ligase HRD1 links ER stress to DNA damage repair by modulating the activity of DNA-PKcs

Expression of ERCC1 in colorectal cancer and its clinical significance

DNA damage triggers tubular endoplasmic reticulum extension to promote apoptosis by facilitating ER-mitochondria signaling

ERCC1 mutations impede DNA damage repair and cause liver and kidney dysfunction in patients